{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T19:07:02Z","timestamp":1789240022016,"version":"build-2803163510"},"reference-count":32,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T00:00:00Z","timestamp":1567296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T00:00:00Z","timestamp":1567296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100007859","name":"University of Kansas","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007859","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journalofsubstanceabusetreatment.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Substance Abuse Treatment"],"published-print":{"date-parts":[[2019,9]]},"DOI":"10.1016\/j.jsat.2019.06.004","type":"journal-article","created":{"date-parts":[[2019,6,7]],"date-time":"2019-06-07T20:12:37Z","timestamp":1559938357000},"page":"42-50","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"special_numbering":"C","title":["Nowhere to go? Examining facility acceptance levels for serving individuals using medications for opioid used disorder"],"prefix":"10.1016","volume":"104","author":[{"given":"Nancy J.","family":"Kepple","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amittia","family":"Parker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Whitmore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle","family":"Comtois","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jsat.2019.06.004_bb0005","author":"American Society of Addiction Medicine (ASAM)"},{"issue":"1","key":"10.1016\/j.jsat.2019.06.004_bb0010","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1111\/jrh.12307","article-title":"Geographic distribution of providers with a DEA waiver to prescribe buprenorphine for the treatment of opioid use disorder: A 5-year update","volume":"35","author":"Andrilla","year":"2019","journal-title":"The Journal of Rural Health"},{"key":"10.1016\/j.jsat.2019.06.004_bb0015","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.npls.2016.01.001","article-title":"How to plan and perform a qualitative study using content analysis","volume":"2","author":"Bengtsson","year":"2016","journal-title":"Nursing Plus Open"},{"issue":"1","key":"10.1016\/j.jsat.2019.06.004_bb0020","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1097\/ADM.0000000000000359","article-title":"A case of opioid overdose and subsequent death after medically supervised withdrawal: The problematic role of rapid tapers for opioid use disorder","volume":"12","author":"Chang","year":"2018","journal-title":"Journal of Addiction Medicine"},{"issue":"11","key":"10.1016\/j.jsat.2019.06.004_bb0025","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1001\/jamapediatrics.2018.2143","article-title":"Receipt of timely addiction treatment and association of early medication treatment with retention in care among youths with opioid use disorder","volume":"172","author":"Hadland","year":"2018","journal-title":"JAMA Pediatrics"},{"key":"10.1016\/j.jsat.2019.06.004_bb0030","series-title":"Drug overdose deaths in the United States, 1999\u20132016. NCHS data brief, no 273","author":"Hedegaard","year":"2017"},{"key":"10.1016\/j.jsat.2019.06.004_bb0035","article-title":"The role of recovery support services in recovery-oriented systems of care","author":"Kaplan","year":"2008"},{"issue":"10","key":"10.1016\/j.jsat.2019.06.004_bb0040","doi-asserted-by":"crossref","first-page":"4102","DOI":"10.3390\/ijerph8104102","article-title":"Improving public health through access to and utilization of medication assisted treatment","volume":"8","author":"Kresina","year":"2011","journal-title":"International Journal of Environmental Research and Public Health"},{"issue":"10118","key":"10.1016\/j.jsat.2019.06.004_bb0045","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/S0140-6736(17)32812-X","article-title":"Comparative effectiveness of extended-release naltrexone versus buprenorphine-naloxone for opioid relapse prevention (X: BOT): A multicentre, open-label, randomised controlled trial","volume":"391","author":"Lee","year":"2018","journal-title":"The Lancet"},{"issue":"2","key":"10.1016\/j.jsat.2019.06.004_bb0050","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1080\/10826084.2017.1325376","article-title":"Primary care physicians' views about prescribing methadone to treat opioid use disorder","volume":"53","author":"Livingston","year":"2018","journal-title":"Substance Use & Misuse"},{"key":"10.1016\/j.jsat.2019.06.004_bb0060","series-title":"Regression models for categorical dependent variables using Stata","author":"Long","year":"2006"},{"key":"10.1016\/j.jsat.2019.06.004_bb9005","article-title":"Effects of medication-assisted treatment on mortality among opioids users: A systematic review and meta-analysis","author":"Ma","year":"2018","journal-title":"Molecular Psychiatry"},{"key":"10.1016\/j.jsat.2019.06.004_bb0065","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1007\/s10597-017-0218-4","article-title":"Oxford house residents' attitudes toward medication assisted treatment use in fellow residents","volume":"54","author":"Majer","year":"2018","journal-title":"Community Mental Health Journal"},{"key":"10.1016\/j.jsat.2019.06.004_bb0070","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD002207.pub4","article-title":"Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence","author":"Mattick","year":"2014","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"2","key":"10.1016\/j.jsat.2019.06.004_bb0075","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1080\/10826084.2017.1342662","article-title":"Medication-assisted treatment for opioid addiction in the United States: Critique and commentary","volume":"53","author":"McElrath","year":"2018","journal-title":"Substance Use & Misuse"},{"issue":"2","key":"10.1016\/j.jsat.2019.06.004_bb0080","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1080\/10826084.2017.1404106","article-title":"Medication-assisted treatment (MAT) for opioid addiction: Introduction to the special issue","volume":"52","author":"McElrath","year":"2018","journal-title":"Substance Use & Misuse"},{"key":"10.1016\/j.jsat.2019.06.004_bb0085","series-title":"Qualitative data analysis","author":"Miles","year":"2014"},{"key":"10.1016\/j.jsat.2019.06.004_bb0090","series-title":"Principles of drug addiction treatment: A research-based guide","author":"National Institute on Drug Abuse","year":"2018"},{"key":"10.1016\/j.jsat.2019.06.004_bb0095","series-title":"The content analysis guidebook","author":"Neuendorf","year":"2016"},{"key":"10.1016\/j.jsat.2019.06.004_bb9000","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.jsat.2017.04.016","article-title":"Relapse to opioid use disorder after inpatient treatment: Protective effect of injection naltrexone","volume":"85","author":"Nunes","year":"2018","journal-title":"Journal of Substance Abuse Treatment"},{"key":"10.1016\/j.jsat.2019.06.004_bb9010","series-title":"MLOGITROC: Stata module to calculate multiclass ROC Curves and AUC from Multinomial Logistic Regression","author":"Peterson","year":"2010"},{"issue":"2","key":"10.1016\/j.jsat.2019.06.004_bb0100","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1080\/00952990.2017.1362419","article-title":"The mixed message behind \u201cMedication-Assisted Treatment\u201d for substance use disorder","volume":"44","author":"Robinson","year":"2018","journal-title":"The American Journal of Drug and Alcohol Abuse"},{"issue":"6","key":"10.1016\/j.jsat.2019.06.004_bb0105","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1016\/j.addbeh.2011.01.032","article-title":"Using medication-assisted treatment for substance use disorders: Evidence of barriers and facilitators of implementation","volume":"36","author":"Roman","year":"2011","journal-title":"Addictive Behaviors"},{"key":"10.1016\/j.jsat.2019.06.004_bb0110","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.15585\/mmwr.mm655051e1","article-title":"Increases in drug and opioid-involved overdose deaths\u2014United States, 2010\u20132015","volume":"65","author":"Rudd","year":"2016","journal-title":"MMWR. Morbidity and Mortality Weekly Report"},{"issue":"5","key":"10.1016\/j.jsat.2019.06.004_bb0115","doi-asserted-by":"crossref","first-page":"917","DOI":"10.2105\/AJPH.2012.301049","article-title":"Opioid agonist treatments and heroin overdose deaths in Baltimore, Maryland, 1995\u20132009","volume":"103","author":"Schwartz","year":"2013","journal-title":"American Journal of Public Health"},{"issue":"4","key":"10.1016\/j.jsat.2019.06.004_bb9015","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1007\/s11126-018-9589-0","article-title":"Ending the opioid epidemic by changing the culture","volume":"89","author":"Sederer","year":"2018","journal-title":"Psychiatric Quarterly"},{"issue":"5","key":"10.1016\/j.jsat.2019.06.004_bb0120","doi-asserted-by":"crossref","first-page":"642","DOI":"10.2105\/AJPH.2018.304338","article-title":"Impact of Medicaid expansion on access to opioid analgesic medications and medication-assisted treatment","volume":"108","author":"Sharp","year":"2018","journal-title":"American Journal of Public Health"},{"issue":"1","key":"10.1016\/j.jsat.2019.06.004_bb0125","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1177\/0899764003257494","article-title":"Typology of religious characteristics of social service and educational organizations and programs","volume":"33","author":"Sider","year":"2004","journal-title":"Nonprofit and Voluntary Sector Quarterly"},{"key":"10.1016\/j.jsat.2019.06.004_bb0130","doi-asserted-by":"crossref","first-page":"j1550","DOI":"10.1136\/bmj.j1550","article-title":"Mortality risk during and after opioid substitution treatment: Systematic review and meta-analysis of cohort studies","volume":"357","author":"Sordo","year":"2017","journal-title":"BMJ"},{"key":"10.1016\/j.jsat.2019.06.004_bb0135","article-title":"National survey of substance abuse treatment services (N-SSATS; 2016): Data on substance abuse treatment facilities","author":"Substance Abuse and Mental Health Services Administration","year":"2017"},{"issue":"12","key":"10.1016\/j.jsat.2019.06.004_bb0140","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1001\/jamapsychiatry.2017.3206","article-title":"Effectiveness of injectable extended-release naltrexone vs daily buprenorphine-naloxone for opioid dependence: A randomized clinical noninferiority trial","volume":"74","author":"Tanum","year":"2017","journal-title":"JAMA Psychiatry"},{"issue":"3","key":"10.1016\/j.jsat.2019.06.004_bb0145","doi-asserted-by":"crossref","first-page":"190","DOI":"10.7326\/M18-1397","article-title":"Overdose prevention through medical treatment of opioid use disorders","volume":"169","author":"Volkow","year":"2018","journal-title":"Annals of Internal Medicine"}],"container-title":["Journal of Substance Abuse Treatment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0740547218306354?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0740547218306354?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T19:49:52Z","timestamp":1760039392000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0740547218306354"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9]]},"references-count":32,"alternative-id":["S0740547218306354"],"URL":"https:\/\/doi.org\/10.1016\/j.jsat.2019.06.004","relation":{},"ISSN":["0740-5472"],"issn-type":[{"value":"0740-5472","type":"print"}],"subject":[],"published":{"date-parts":[[2019,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Nowhere to go? Examining facility acceptance levels for serving individuals using medications for opioid used disorder","name":"articletitle","label":"Article Title"},{"value":"Journal of Substance Abuse Treatment","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jsat.2019.06.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}